Form 4: Inmune Bio CEO Moss Granted 750,000 Stock Options

Inmune Bio, Inc. CEO David J. Moss received a grant of 750,000 stock options with a $1.48 exercise price, vesting over four years.

Summary

• David J. Moss, CEO and Director of Inmune Bio, Inc. (INMB), was granted 750,000 stock options.
• The options have an exercise price of $1.48 per share.
• The grant date for these options was December 1, 2025.
• The options will expire on November 23, 2035.
• Vesting schedule: 25% of the options will vest 12 months from the grant date.
• The remaining 75% will vest pro rata on a monthly basis over the subsequent three years (1/36 per month).
• Full vesting (100%) will occur on the four-year anniversary of the grant date.
• The options were granted under the Issuer's Second Amended and Restated 2021 Stock Incentive Plan.

Sentiment

Score: 7

Explanation: The option grant is a positive signal of management's long-term commitment and alignment with shareholder interests, though it introduces potential future dilution. It's a standard compensation practice.

Positives

• The option grant aligns the interests of CEO David J. Moss with those of shareholders, incentivizing long-term company performance.
• The significant number of options (750,000) demonstrates a substantial commitment to the company's future success by a key executive.
• The four-year vesting schedule encourages sustained leadership and strategic execution over an extended period.

Negatives

• The issuance of additional stock options could lead to potential future dilution for existing shareholders if the options are exercised.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent risks associated with stock-based compensation (e.g., potential future dilution).

Future Outlook

The vesting schedule of the options, extending over four years, implies a long-term strategic outlook and commitment from the CEO to drive future company performance.

Management Comments

• The grant of 750,000 stock options to CEO David J. Moss is intended to align his long-term incentives with shareholder value creation.

Industry Context

Stock option grants to key executives are a standard practice in the biotechnology and pharmaceutical industries, particularly for companies like Inmune Bio, Inc. (INMB) which are often in development stages. This practice aims to retain talent and incentivize performance tied to long-term growth and clinical milestones, which are critical in this sector.

Comparison to Industry Standards

• The grant of 750,000 options to a CEO is a significant equity award, comparable to grants seen in similar-sized biotech companies aiming to incentivize leadership through critical development phases.
• The four-year vesting schedule, with a one-year cliff and monthly pro-rata vesting thereafter, is a common structure for executive equity compensation plans across the industry, balancing retention with performance incentives.
• An exercise price of $1.48, matching the stock price on the grant date, is typical for 'at-the-money' options, aligning the executive's gains directly with future stock price appreciation.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential for increased shareholder value if the CEO's incentives lead to improved company performance.
• Employees: May signal stability and confidence in leadership, potentially boosting morale.

Next Steps

• The options will begin vesting 12 months from the grant date (December 1, 2025).
• The remaining unvested options will continue to vest monthly over the subsequent three years.
• Full vesting of the options will occur on the four-year anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event, specifically an option grant to the CEO. While it aligns management's interests with shareholders and incentivizes long-term performance, it does not present new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Inmune Bio, INMB, David J Moss, Stock Options, CEO, Executive Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Vesting Schedule